Combined C3b and Factor B Autoantibodies and MPGN Type II

    December 2011 in “ New England Journal of Medicine
    Qian Chen, Dominik N. Müller, Birgit Rudolph, Andrea Hartmann, Eberhard Kuwertz-Bröking, Kaiyin Wu, Michael Kirschfink, Christine Skerka, Peter F. Zipfel
    From the encyclopedia
    Finasteride →

    Frontline, gold standard treatment for combatting androgenic alopecia

    Dutasteride →

    Heavy duty finasteride that comes with higher risks

    Studysummary This article discusses the FDA's decision not to approve 5α-reductase inhibitors for prostate cancer prevention, citing an increase in high-grade tumors but no mortality evidence, and reports no new results.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →